Why mAbs Matter
Quality Matters
FEBRUARY 6, 2025
As more monoclonal antibody (mAb) therapies are developed (1 in 3 new drugs are monoclonal antibodies1) and as patent exclusivity expires, these treatments are becoming more widely available. Antigens are usually structures on the outside of the disease-causing agent. Anything that triggers an immune response is called an antigen.
Let's personalize your content